Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 210,104,068 papers from all fields of science
Search
Sign In
Create Free Account
EMD 72000
Known as:
EMD-72000
, EMD72000
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
matuzumab
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Targeted signal-amplifying enzymes enhance MRI of EGFR expression in an orthotopic model of human glioma.
M. Shazeeb
,
C. Sotak
,
M. Deleo
,
A. Bogdanov
Cancer Research
2011
Corpus ID: 2886787
Epidermal growth factor receptor (EGFR) imaging in brain tumors is essential to visualize overexpression of EGFRvIII variants as…
Expand
Highly Cited
2008
Highly Cited
2008
Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization.
Judith Schmiedel
,
A. Blaukat
,
Shiqing Li
,
T. Knöchel
,
K. Ferguson
Cancer Cell
2008
Corpus ID: 32084527
2008
2008
Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk
Takeshi Yoshida
,
I. Okamoto
,
+5 authors
K. Nakagawa
International Journal of Cancer
2008
Corpus ID: 35408889
Molecular inhibition of the epidermal growth factor receptor (EGFR) is a promising anticancer strategy, and monoclonal antibodies…
Expand
2008
2008
Matuzumab Short-Term Therapy in Experimental Pancreatic Cancer: Prolonged Antitumor Activity in Combination with Gemcitabine
A. Kleespies
,
I. Ischenko
,
+5 authors
C. Bruns
Clinical Cancer Research
2008
Corpus ID: 14483563
Purpose: The epidermal growth factor receptor ErbB-1 is commonly expressed in pancreatic cancer and ErbB-1 targeting has shown…
Expand
Highly Cited
2007
Highly Cited
2007
A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies.
M. Seiden
,
H. Burris
,
+5 authors
F. Muggia
Gynecologic Oncology
2007
Corpus ID: 21216034
Review
2005
Review
2005
Monoclonal antibodies targeting the epidermal growth factor receptor.
R. Bianco
,
G. Daniele
,
F. Ciardiello
,
G. Tortora
Current Drug Targets
2005
Corpus ID: 25839054
The epidermal growth factor receptor (EGFR, HER1) autocrine pathway contributes to a number of highly relevant processes in…
Expand
2005
2005
Magnetic resonance imaging in an orthotopic rat model: Blockade of epidermal growth factor receptor with EMD72000 inhibits human pancreatic carcinoma growth
C. Bangard
,
A. Gossmann
,
A. Papyan
,
S. Tawadros
,
M. Hellmich
,
C. Bruns
International Journal of Cancer
2005
Corpus ID: 926696
The purpose of our research was to investigate the antiangiogenic effect of the epidermal growth factor receptor monoclonal…
Expand
2005
2005
A phase II Trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody in subjects with heavily treated and platinum-resistant advanced Mullerian malignancies
M. Seiden
,
H. Burris
,
+6 authors
F. Muggia
2005
Corpus ID: 75663232
3151 Background: A high proportion of ovarian tumors express the epidermal growth factor receptor (EGFR). Preclinical and…
Expand
2005
2005
A phase I study of a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody “EMD72000 (Matuzumab)” administered weekly in Japanese patients with advanced solid tumors; safety, PK…
T. Doi
,
A. Ohtsu
,
+7 authors
F. Rojo
2005
Corpus ID: 79216533
3077 Background: Matuzumab is a humanized monoclonal antibody binding to the EGFR with higher affinity than natural ligands (eg…
Expand
Highly Cited
2004
Highly Cited
2004
Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor.
U. Vanhoefer
,
M. Tewes
,
+10 authors
J. Baselga
Journal of Clinical Oncology
2004
Corpus ID: 35179922
PURPOSE To investigate the safety and tolerability and to explore the pharmacokinetic and pharmacodynamic profile of the…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE